AP NEWS

Global Burkitt Lymphoma Therapeutics Market 2018-2022 - Key Vendors Are Biogen, F. Hoffmann-La Roche, Merck Sharp & Dohme, Novartis & Spectrum Pharmaceuticals - ResearchAndMarkets.com

September 21, 2018

DUBLIN--(BUSINESS WIRE)--Sep 21, 2018--The “Global Burkitt Lymphoma Therapeutics Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The Global Burkitt Lymphoma Market to grow at a CAGR of 3.07% during the period 2018-2022.

Burkitt lymphoma market 2018-2022 has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Increasing strategic alliances in the field of oncology will be one of the major trends in the market as vendors in the global oncology drugs market are regularly engaging in strategic alliances to strengthen their market position. Such alliances help these vendors consolidate their position and extend their geographical reach.

According to the report, one driver influencing this market is the rapid progression of Burkitt lymphoma requires immediate medical attention. Burkitt lymphoma is recognized as one of the fastest growing tumours in humans and is highly fatal if left untreated during the early stages.

Further, the report states that one challenge affecting this market is the high cost of the treatment. The chemotherapy drugs used in the treatment of Burkitt lymphoma are expensive. The high cost of chemotherapy drugs is one of the major challenges faced by the global Burkitt lymphoma therapeutics market.

Key vendors

Biogen F. Hoffmann-La Roche Merck Sharp & Dohme Novartis Spectrum Pharmaceuticals

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: DISEASE OVERVIEW

PART 05: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 06: MARKET SIZING

Market definition Market sizing 2017 Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

PART 08: PIPELINE

PART 09: MARKET SEGMENTATION BY DRUG CLASS

Segmentation by drug class Comparison by drug class Biological - Market size and forecast 2017-2022 Small molecule - Market size and forecast 2017-2022 Market opportunity by drug class

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

Geographical segmentation Regional comparison Key leading countries Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

PART 14: MARKET TRENDS

PART 15: VENDOR LANDSCAPE

PART 16: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors

For more information about this report visit https://www.researchandmarkets.com/research/75nnhz/global_burkitt?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180921005401/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Lymphoma Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/21/2018 11:33 AM/DISC: 09/21/2018 11:33 AM

http://www.businesswire.com/news/home/20180921005401/en

AP RADIO
Update hourly